Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -0.40% 62.50p 62.00p 63.00p 62.75p 62.50p 62.75p 89,669 11:01:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.1 -5.1 - 61.86

Futura Medical (FUM) Latest News

More Futura Medical News
Futura Medical Takeover Rumours

Futura Medical (FUM) Share Charts

1 Year Futura Medical Chart

1 Year Futura Medical Chart

1 Month Futura Medical Chart

1 Month Futura Medical Chart

Intraday Futura Medical Chart

Intraday Futura Medical Chart

Futura Medical (FUM) Discussions and Chat

Futura Medical Forums and Chat

Date Time Title Posts
24/10/201621:58FUTURA a winner for 20151,783
07/9/201611:07FUM delivering on sex,pain and rock'n'roll11,383
21/6/201608:43fum reality1

Add a New Thread

Futura Medical (FUM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
24/10/2016 16:27:0962.151,500932.25O
24/10/2016 16:14:0262.151,114692.35O
24/10/2016 15:27:5862.651,000626.50O
24/10/2016 14:46:3262.526,3823,990.03O
24/10/2016 14:32:0362.151,284798.01O
View all Futura Medical trades in real-time

Futura Medical (FUM) Top Chat Posts

Futura Medical Daily Update: Futura Medical is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 62.75p.
Futura Medical has a 4 week average price of 64.49p and a 12 week average price of 48.26p.
The 1 year high share price is 96.25p while the 1 year low share price is currently 14.50p.
There are currently 98,982,208 shares in issue and the average daily traded volume is 106,023 shares. The market capitalisation of Futura Medical is £61,863,880.
isaready: Ready to go again? Futura Medical tipped to rally Share 09:11 07 Oct 2016 The dust has settled after August's 300% rally, but technical analysis suggests the price will move higher again. Happy trader Trader's delight: Futura shares could reach 100p to 120p in the coming months. As it is a £60mln valued company with plans to launch a disruptive new product into a multibillion dollar market, it is probably not shocking to hear an expert say shares in Futura Medical Plc (LON:FUM) ought to go higher. Futura’s price jumped some 300% in August – thanks to a breakthrough with its new erectile dysfunction product – and now, following a pull-back and a pause for breath it is predicted that there can be a fresh rally. Technical analyst Zak Mir has noted that Futura had seen a significant transformation in recent weeks and he highlighted that the share price chart now showed a ‘good consolidation’ since the summer breakout. “The shares aren’t even overbought now, they’ve cooled off” Mir said in a Tips TV segment for Proactive Investors. WATCH Zak Mir's analysis right now The chart guru believes the share can push on to reach between 100p to 120p over the next three to six months – and that’s a target that he says is valid whilst the price holds above the 50-day average, around the 45p mark. Mir adds, however, that when it comes to timing an entry technically minded traders may be conservative. “I think you probably wait if you’re really cautious. You wait for the RSI to go back towards the oversold area. So maybe there’s a move below 60p that puts the RSI lower. You’ll feel at least that you’re not paying too much money near the top. “But we have come back already, we are off the top already. So from these areas probably going in stages is the right way.” A breakthrough The uptick in Futura’s fortunes coincided with some very positive data from a 232-strong trial of its erectile dysfunction drug, MED2002. It boasts one advantage that marks it out from the current treatments - pills such as Viagra and Cialis - and that’s speed of onset. For while the little blue pill can take up to 30 minutes to work its magic, Eroxon, a gel applied directly to the nether regions, takes effect in as little as five minutes. Stockbroker N+1 Singer, citing Futura’s own market research, N+1 suggests that based on this superior onset of action, the safety profile and the switch to selling Eroxon over the counter, annual revenues could be in excess of £380mln (US$500mln). Sales of drugs treating erectile dysfunction currently stands at £3.8bn (US$5bn). If the new discovery does achieve anywhere near its potential, then the bout of profit-taking witnessed in recent weeks may be misplaced. Futura isn’t a one-trick pony. The same delivery mechanism used for Eroxon, a gel that penetrates the skin, could be used to deliver all sorts of drugs, including pain relief. The company has, crucially, solved the shelf-life problems with its CSD500 condoms, designed to help men maintain an erection and maximise penile size. Regulatory submissions to enable an extended shelf life of at least 18 months have been filed for both its European manufacturer and for TTK Protective Devices Limited, the Indian manufacturer with whom it has also signed a distribution agreement. Futura is also making progress with out-licensing talks for the topical pain relief gels, and it is now at the heads-of-terms stage with a number of potential partners. In a recent Proactive Investors interview Futura chief executive James Barder said: “We’ve already got approval for the product in Europe, but that was with one German manufacturer where we currently have a shelf life of twelve months,” “The problem with that is that most retailers want to have at least twelve months shelf life when the product hits the store, so bearing in mind the logistics of the supply chain you’re not going to be able to achieve that unless you’ve got eighteen months.” “Now that we’ve got that it will help us move forward.” Barder added that the company expects, and is already seeing, a lot of interest in the product.
j777j: Share price is lower than it was three years ago and yet the co has multiple products at commercialisation stage. JB was asked about the cash situation in a recent video interview ,where he hinted at it not being an issue because they will be receiving upfront,milestone and royalty payments,presumably this year. The share price should be multiples higher. Gla Ps Anything but holding pounds sterling must be a good bet.
isaready: This share price will be news driven, clearly. Any sign of actual possible deals, real cashflow flowing in, will move the share price. All we can do is wait and see what will happen and when. I am not sure what the broker note will show other than what we know. They may hold back from ramping it with a price unless they have real info on possible monetary information on possible deals. Hopefully we will see dble bottom and a nice bounce soon enough.
loobrush: on lse this morning I must admit that I am surprised by the share price reaction and have concluded that some investors have not understood the story here and would point out the following. (Med 2002) is ALREADY AVAILABLE in the UK. As previously announced it is available as as special. This means that all you have to do is ask your Doctor for it and he can prescribe it as a special for you if he considers it suitable. Not only that but its free. Join the queue at the Doctors. Licensing-during the webcast he advised that both the pain portfolio and Eroxogen are undergoing licencing negotiations and were following the same process in that they were looking to licence out BOTH products as soon as they have the deal they want. Also that the Big difference with (Med 2002)to all other products is that -it should be able to be sold OTC (over the counter). No other product has this ability and this makes it stand out head over shoulders against anything. The potential is still huge and this will be recognised in the days and weeks ahead and the share price,which is ridiculously low, will rise to a more appropriate level, or a bid will come for the company.
j777j: Re 1147 -Clown This interesting too on top of a $500 million market for the erectogenic gel Pain gel Our objective is for our products to be best in class. The rationale for this is that the National Institute for Health and Care Excellence (NICE) gives clear guidance to physicians to prescribe topical NSAIDs in the first instance for joint pain associated with osteoarthritis, in preference to oral NSAIDs, owing to concerns on the long term use of oral NSAIDs. This means that the best-in-class topical treatment should be the first choice for doctors in the initial treatment of pain and therefore represents a substantial opportunity in a market with global sales estimated at US$2.9 billion. Condom 10% of a $6 billion market do the maths. $500 million Erectogenic gel market share $2.9 billion Pain gel market share $600 million condom market share 2.5% royalties would be $100 million a year to Futura On 10X that would be a 740p share price On 15X you are at 1140p share price gla
weildy2: What is the shelf life of THIS product ? FUM screwed up and were less than open about the problems with CSD500. Whilst I am delighted with the significant rise in the share price, I would be VERY wary of committing further funds. I have been in this share now for six years (please feel free to check my posting history) and I hold a significant number of shares. I am not a de-ramper, I certainly don't want to shoot myself in the foot, but please don't get carried away with flights of fantasy. Check the history of FUM before you commit your hard earned cash. As I said, I am delighted with the rise in the SP, but those of you new to FUM, please be cautious. FUM do not have a reputation for openness and have misled us in the past.
loobrush: FROM LSE Another product of Futura which also has huge potential is their pain relief portfolio of products. PRODUCTS FOR PAIN RELIEF TPR100,-TPR100 will provide topical pain relief. The product incorporates a non-steroidal anti-inflammatory drug ("NSAID") and utilises Futura's DermaSys� technology. "These were recently tested and compared against the current markey leading products with brilliant results-- Iquote-- TIB200-TIB200 in a recent randomised, double blind, placebo and active-controlled, crossover clinical study to assess the efficacy and safety of TIB200 against a market-leading ibuprofen gel, against orally delivered ibuprofen and against a placebo of TIB200's gel, TIB200 achieved its primary endpoint and presents an exciting product opportunity. No comparator product, topical or oral outperformed TIB200. SPR300--.SPR300 is a topical gel combining methyl salicylate and menthol with the DermaSys� delivery system. SPR300 has been shown to achieve in excess of four times higher penetration through isolated human skin compared with the UK's best-selling topically applied methyl salicylate/menthol-based topical pain relief product, Deep Heat�. In addition SPR300 was directly compared with the best-selling over-the-counter topically applied gels sold in the USA, Icy Hot� and Bengay�, and showed similarly improved permeation rates. SPR300, together with TPR100 and TIB200, presents a portfolio opportunity for a potential licensing partner. Futura has received interest in the portfolio and elements of the portfolio for various territories worldwide and it is our intention to build greater value in the portfolio prior to making a licensing decision." There is a huge market in pain relief and in partcular with older people with arthritis and the licensing of these BEST IN CLASS pain killers should mean a huge up front payment and royalties. How much-I am doing some resarch on this. Add this value to the Erection Gel and we are talking a share price lot higher than todays share price.
loobrush: This says it all-- iii Thu 12:58 Re: Best guesses? TonyDeadeye 1UP The share price decline prompted me to email Mr Barder who replied within an impressive 5 minutes as follows: "I can understand your concern over the recent share price weakness. I can also add that we are equally frustrated by this recent weakness. There is nothing that has materially happened in the company to cause this drop in share price although I understand there is a seller in the market which is causing this drop. I have no further details about the nature of or circumstances of this seller." Needs another institutional holder to get interested, maybe at this cheap price someone will be tempted.
lbo: That is a fair criticism in light of the disappointing share price performance. But I remember no shareholders proposed any resolutions at the AGM regarding the Board, its remuneration or share price performance? Why is that? I do remember one or two posters on here said they gave the Board a hard time in Q&A but I did not see any sign of shareholders looking for change on the Board of Directors. So it would seem to me more would be gained by asking shareholders why they are seemingly happy with progress and the share price and taking no action. Or maybe most on here are not even shareholders anymore but disgruntled small PIs who invested when Futura was overhyped and are now very bitter. I do recollect a lot of posters on here linked to Iofina which I also see was even more overhyped. So this Q&A now would be more of an informative and elightening process. We have even had Hendersons increasing their shareholding during this time. Why have they taken a seemingly opposing view of support? Is it because they are buying in at more realistic valuation and after more real progress has been made in products terms? But perhaps the support for the Board will change by the time of the next AGM or even before if the share price does not perform as well as the faith Mr Barder seems to continue to have in Futura. Time will tell who is right and who is wrong and who will be rewarded by showing support or who may suffer irrecoverable financial loss. I would also say that it might be unfair to say he has not a lot to loose also now. Because if he does not perform by the next AGM in terms of share price then he will surely be seen by all as having failed and not just by shareholders. And by this I refer to his own family who I believe also have a substantial shareholding and vested interest in Futura.
sceptic bull: Looking to get back into the small cap markets and I like the look of FUM as one of many many candidates to invest. Attractions: The product will sell itself regardless of marketing ability of partner with plenty of mainstream media coverage. Low cost base of Company therefore any funding will not be significant. If the product works as described then it will get a good % of the market The IP. The main players would have tried very hard to produce their own in-house OTC product but clearly they haven't been able to. Eddison's market share projections and target share price look conservative. Question marks Trial was quite limited. 100 participants. Why no follow up trial to assist marketing claims? How conclusive was the trial? I doubt if this is a big issue but a further conclusive trial would have given me more confidence. If this product works then FUM will get a very significant share of the market. Why did RB relinquish? Not especially important as big companies can make silly decisions. Drop in share price. Are FUM doing a placing? Markets for funding small caps usually exact a discount. Although if reason for drop is some placing leak then I doubt it has further to fall. Despite being in control of production issues FUM cannot control launch date for CSD Limited progress on pain relief products so FUM share price is very reliant on CSD500 Any potential competition. Unlikely as there has been plenty of time to produce something. How good is the board of directors and especially the CEO? Seems competent but not over inspiring.
Futura Medical share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20161024 23:36:52